GlassScriptPhysician profile
Christopher J Vandelune
NPI 1871598557
$2,853.57
in general payments reported to CMS, 2019-2025
33 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $159 · 2021: $551 · 2022: $487 · 2023: $505 · 2024: $666 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,656 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.28 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $558.74 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $445.87 | 2020-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.31 | 2021-2025 | Jardiance |
| Abbvie INC. | $198.92 | 2021-2025 | Ubrelvy |
| Lilly USA, LLC | $172.31 | 2020-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $165.74 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $148.46 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.01 | 2022-2024 | |
| Astellas Pharma US INC | $86.16 | 2022-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $83.10 | 2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $82.21 | 2021-2022 | |
| Glaxosmithkline, LLC. | $75.78 | 2023-2025 | Shingrix, Arexvy, Nucala |
| Biohaven Pharmaceuticals, INC. | $50.40 | 2021 | |
| Novartis Pharmaceuticals Corporation | $46.85 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.56 | 2024-2025 | Caplyta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $41.85 | 2021-2025 | Eliquis |
| Abbott Laboratories | $31.90 | 2022 | |
| Merck Sharp & Dohme LLC | $27.56 | 2021 | |
| Verona Pharma, INC. | $27.30 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $22.12 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $20.21 | 2023 | Trintellix |
| Medtronic, INC. | $18.49 | 2023 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $17.62 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.20 | 2022 | |
| Mylan Specialty L.P. | $16.93 | 2022 | |
| Acadia Pharmaceuticals INC | $15.63 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.13 | 2022 | |
| Allergan, INC. | $13.42 | 2020 | |
| Boston Scientific Corporation | $13.23 | 2022 | |
| Genentech USA, INC. | $12.76 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.76 | 2022 | |
| Galderma Laboratories, L.P. | $12.25 | 2021 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Vandelune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.